Wolf Group Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-9,024
| Closed | -$1.6M | – | 103 |
|
|
2021
Q2 | $1.6M | Buy |
9,024
+121
| +1% | +$21K | 0.86% | 47 |
|
|
2021
Q1 | $1.46M | Buy |
8,903
+217
| +2% | +$35.7K | 0.84% | 47 |
|
|
2020
Q4 | $1.43M | Sell |
8,686
-68
| -0.8% | -$10.1K | 0.89% | 46 |
|
|
2020
Q3 | $1.25M | Sell |
8,754
-48
| -0.5% | -$5.95K | 0.87% | 44 |
|
|
2020
Q2 | $971K | Buy |
8,802
+102
| +1% | +$11.3K | 0.72% | 52 |
|
|
2020
Q1 | $868K | Buy |
8,700
+129
| +2% | +$16.7K | 0.72% | 52 |
|
|
2019
Q4 | $1.28M | Sell |
8,571
-129
| -1% | -$17.6K | 0.84% | 48 |
|
|
2019
Q3 | $1.11M | Buy |
8,700
+109
| +1% | +$14.6K | 0.77% | 46 |
|
|
2019
Q2 | $1.23M | Sell |
8,591
-319
| -4% | -$42.9K | 0.85% | 40 |
|
|
2019
Q1 | $1.27M | Buy |
8,910
+4
| +0% | +$522 | 0.88% | 37 |
|
|
2018
Q4 | $1.1M | Buy |
8,906
+59
| +0.7% | +$8.75K | 0.82% | 41 |
|
|
2018
Q3 | $1.49M | Sell |
8,847
-1,240
| -12% | -$213K | 0.97% | 39 |
|
|
2018
Q2 | $1.74M | Sell |
10,087
-668
| -6% | -$109K | 1.13% | 35 |
|
|
2018
Q1 | $1.62M | Sell |
10,755
-1,662
| -13% | -$244K | 1.08% | 37 |
|
|
2017
Q4 | $1.67M | Sell |
12,417
-492
| -4% | -$68.2K | 1.04% | 40 |
|
|
2017
Q3 | $1.81M | Sell |
12,909
-3,487
| -21% | -$527K | 1.26% | 29 |
|
|
2017
Q2 | $2.55M | Sell |
16,396
-4,054
| -20% | -$620K | 1.96% | 17 |
|
|
2017
Q1 | $2.97M | Sell |
20,450
-302
| -1% | -$39.3K | 1.95% | 14 |
|
|
2016
Q4 | $2.26M | Sell |
20,752
-1,418
| -6% | -$158K | 1.52% | 26 |
|
|
2016
Q3 | $2.69M | Sell |
22,170
-1,035
| -4% | -$140K | 1.88% | 13 |
|
|
2016
Q2 | $3.28M | Sell |
23,205
-224
| -1% | -$33K | 2.42% | 2 |
|
|
2016
Q1 | $3.06M | Buy |
23,429
+4
| +0% | +$498 | 2.3% | 7 |
|
|
2015
Q4 | $3.29M | Buy |
23,425
+1,752
| +8% | +$243K | 2.45% | 5 |
|
|
2015
Q3 | $2.88M | Sell |
21,673
-1,410
| -6% | -$243K | 2.31% | 7 |
|
|
2015
Q2 | $4.06M | Sell |
23,083
-5
| -0% | -$898 | 2.71% | 3 |
|
|
2015
Q1 | $3.99M | Sell |
23,088
-355
| -2% | -$60.9K | 2.75% | 3 |
|
|
2014
Q4 | $3.84M | Sell |
23,443
-1,060
| -4% | -$176K | 2.78% | 4 |
|
|
2014
Q3 | $3.93M | Sell |
24,503
-285
| -1% | -$43.8K | 2.94% | 2 |
|
|
2014
Q2 | $3.64M | Buy |
24,788
+1,295
| +6% | +$180K | 2.65% | 4 |
|
|
2014
Q1 | $3.26M | Sell |
23,493
-5,760
| -20% | -$867K | 2.52% | 5 |
|
|
2013
Q4 | $3.69M | Buy |
+29,253
| New | +$3.03M | 2.96% | 3 |
|
Other funds holding JAZZ
PCM
Wolf Group Capital Advisors's JAZZ Position: Q3 2021 in Review
Wolf Group Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 9,024 shares — an estimated $1.6M sold.
Wolf Group Capital Advisors first reported a position in JAZZ in Q4 2013 and held it in 31 quarters. The position peaked at $4.06M in Q2 2015. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.
- Wolf Group Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
- Wolf Group Capital Advisors sold 9,024 Jazz Pharmaceuticals shares in Q3 2021, an estimated $1.6M.
- Wolf Group Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 31 quarters.
- Wolf Group Capital Advisors's Jazz Pharmaceuticals position peaked at $4.06M in Q2 2015.
- 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.
Based on Wolf Group Capital Advisors's 13F filing for Q3 2021, filed 20 Oct 2021.